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Objectives
To characterise the progression and treatment of lower urinary
tract symptoms (LUTS) among men aged 45–69 years in the
California Men’s Health Study.
Patients and Methods
A total of 39 222 men, aged 45–69 years, enrolled in the
Southern California Kaiser Permanente Health Plan were
surveyed in 2002–2003 and again in 2006–2007. Those men
who completed both surveys who did not have a diagnosis
of benign prostatic hyperplasia (BPH) and were not on
medication for LUTS at baseline were included in the study
(N = 19 505). Among the men with no or mild symptoms at
baseline, the incidence of moderate/severe LUTS (American
Urological Association Symptom Index [AUASI] score ≥8)
and odds of progression to severe LUTS (AUASI score ≥20)
was estimated during 4 years of follow-up.
Results
Of the 9640 men who reported no/mild LUTS at baseline,
3993 (41%) reported moderate/severe symptoms at follow-up
and experienced a 4-point change in AUASI score on average.
Of these men, 351 (8.8%) had received a pharmacological
treatment, eight (0.2%) had undergone a minimally invasive
or surgical procedure and 3634 (91.0%) had no treatment
recorded. Men who progressed to severe symptoms (AUASI
score ≥20; n = 165) were more likely to be on medication for
BPH (odds ratio [OR] 8.09, 95% confidence interval [CI]
5.77–11.35), have a BPH diagnosis (OR 4.74, 95% CI
3.40–6.61) or have seen a urologist (OR 2.49, 95% CI
1.81–3.43) when compared with men who did not progress
to severe symptoms (AUASI score <20).
Conclusion
These data show that the majority of men who experienced
progression did not have pharmacological or surgical therapy
for their symptoms and, therefore, may prove to be good
candidates for a self-management plan.
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Introduction
Lower urinary tract symptoms are a common and
burdensome condition affecting aging men. It is estimated
that 3.4 million men in the USA aged >60 years have this
condition [1,2]. Not only are LUTS common, but they are also
associated with significant bother and poor quality of life
[3,4]. Each year, >$6 bn is spent on the diagnosis and
treatment of LUTS [5].
In men, LUTS most often occur secondary to BPH or after
prostate cancer treatment. Accurate characterisation of LUTS
from the literature is difficult because of the reliance on
self-report, the dynamic nature of the condition, the
existence of distinct clinical subtypes of LUTS, and the
various time periods over which symptoms are queried [6].
Previous studies suggest that ∼11–34% of men report
experiencing any LUTS in their lifetime, and the prevalence
of symptoms increases with age [6]; however, the majority
of studies to date provide estimates of the prevalence of
LUTS and cannot estimate incidence. The accurate
estimation of the incidence of LUTS would further our
understanding of the natural history of LUTS and, thus,
facilitate research focused on prevention and improved
treatment strategies.
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To date, reports on the incidence and progression of LUTS
come from highly selected clinical trial populations or
population-based samples of mostly white and elderly men
and are therefore limited by their lack of diversity and limited
availability of treatment and utilisation information over time.
Results from the population-based studies suggest that
between a quarter and three-quarters of men experience
progression within 5 years, which strongly correlates with age
[7]. Data from the Olmsted County Study (OCS) suggest that
22% of men with no/mild symptoms at baseline experienced
new-onset moderate/severe LUTS within 4 years [8]. In the
Osteoporotic Fractures in Men study (MrOS), up to 29% of
men with none/mild LUTS at baseline experienced clinically
significant symptom progression within 2 years [9]. Martin
et al. [10] found that three-quarters of Australian men in a
population-based cohort experienced progression of
symptoms over 5 years of follow-up. Data from the Health
Professional Follow-up Study suggest that both incidence and
progression increase sharply with age [7]. Data from clinical
trials evaluating the effect of the pharmaceutical management
of BPH/LUTS progression further support the notion that
LUTS is a progressive condition, as clinically relevant
symptom progression occurred in up to 20% of men with
moderate/severe LUTS in the placebo arms [11–13].
To better develop strategies to manage and treat LUTS,
accurate characterisation of the incidence and progression of
LUTS, as well as a better understanding of treatment patterns
in general practice settings is necessary; therefore, the aim of
the present study was to determine the incidence of new-onset
LUTS while characterising the treatment and progression of
these symptoms over 4 years of follow-up among men
enrolled in the large, multi-ethnic California Men’s Health
Study.
Patients and Methods
California Men's Health Study
The California Men’s Health Study is a multi-ethnic,
prospective cohort study for which recruitment, methods and
population have been described previously [14–16]. Briefly,
men aged 45–69 years, who were members of Northern or
Southern California Kaiser Permanente Health Plans for at
least 1 year before the study were eligible for inclusion.
Eligible participants received questionnaires by post at
baseline to ascertain demographic information, medical, family
and social histories, and current health status and lifestyle
behaviours. A two-stage sampling design was used for
questionnaire mailing, and questionnaire data were linked to
clinical data, including laboratory, hospitalisation and cancer
data from electronic health plan files.
Measurements
For the present study, men from Southern California who
completed both the baseline survey in 2002–2003 and the
follow-up survey in 2006–2007 were included (n = 25 229). Of
these men, those who were not continuous members of
Southern California Kaiser Permanente Health Plan between
surveys were excluded (n = 1506). Because we were interested
in new-onset LUTS, we excluded men with a previous
diagnosis of BPH) before baseline (n = 2733), those being
treated for BPH with medications before baseline (n = 1476)
and men who had undergone a procedure to treat BPH before
baseline (n = 9). As a result, a total of 19 505 men were
included in the present analysis.
Demographic characteristics, including age, race, education,
household income and marital status, and lifestyle
characteristics, e.g. smoking status, were obtained from the
baseline questionnaire. Body mass index was calculated via
self-reported height and weight.
The presence of LUTS was assessed at baseline and follow-up
via the AUA Symptom Index (AUASI). The AUASI is a
seven-item self-administered questionnaire that assesses the
frequency of LUTS over the preceding month [17]. Symptom
frequency questions are measured on a six-point scale from 0
(never) to 5 (always) and summed for a total AUASI score.
Scores 0–7 are considered indicative of no/mild symptoms,
scores 8–19 of moderate symptoms and scores ≥20 of severe
symptoms. A 4-point increase in AUASI score was considered
to indicate clinically relevant progression [11,13,18].
Information regarding BPH diagnosis (International
Classification of Diseases code: ICD-9 600.x) and clinic visits
to urology were ascertained from electronic medical records.
Treatment for BPH/LUTS during this time was abstracted
from electronic medical records and included any use of
α-blockers, 5-α reductase inhibitors or their combination
and/or the use of any minimally invasive or surgical
procedure to treat BPH/LUTS (prostatectomy, transurethral
resection, laser-based or microwave procedures and needle
ablation).
Statistical Analyses
The distribution of demographic, lifestyle and medical
characteristics was compared over levels of baseline AUASI
score using chi-squared tests and t-tests where appropriate.
The distribution of AUASI scores at follow-up was compared
across levels of baseline AUASI score. Also, the distribution
of the change in AUASI score from baseline to follow-up,
categorised as a <4-point change, a 4-point increase (clinical
progression) and a 4-point decrease) was compared across
baseline AUASI categories. The 4-year progression of LUTS
was determined among men with no/mild symptoms at
baseline, as was the proportion of these men who received
treatment during follow-up.
Among men with a baseline score of 0–7, indicating no/mild
symptoms, the distribution of BPH clinical characteristics,
including a diagnosis of BPH, use of BPH medication or
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procedure and urology clinic visits, were compared across
levels of follow-up AUASI score. The associations of these
BPH clinical characteristics with the progression to severe
LUTS symptoms (AUASI score ≥20) were estimated using
multivariable logistic regression models adjusted for BPH
medication, BPH procedure, urology clinic visits, BPH
diagnosis and age. An α level of 0.05 was used to determine
statistical significance and all analyses were performed using
SAS 9.2 (Cary, NC, USA).
Results
Table 1 shows the distribution of baseline demographic and
BPH characteristics by baseline AUASI category. Baseline
symptom score was positively associated with age; a greater
proportion of older men reported moderate/severe symptoms
(P < 0.001). Men who reported no/mild symptoms at baseline
were slightly more likely to be white, report that they were
never smokers and have a slightly lower body mass index on
average (Table 1). A diagnosis of BPH, the use of BPH/LUTS
medication, a history of a procedure to treat BPH/LUTS and
urology visits were all more common among men who
reported severe symptoms at baseline.
Figure 1 shows the distribution of LUTS symptoms at
follow-up and the change in AUASI scores between baseline
and follow-up, stratified by baseline AUASI score category. Of
the 9701 men who reported no/mild symptoms at baseline,
>40% reported a progression in their symptoms, with 3828
(39.7%) reporting moderate symptoms and 165 (1.7%)
reporting severe symptoms at follow-up 4 years later. Of the
8974 men who reported moderate symptoms at baseline,
the majority did not progress, again reporting moderate
symptoms at follow-up (70.6%). Among men with severe
symptoms at baseline, 43.3% reported moderate symptoms
and 47.9% reported severe symptoms at follow-up.
Among men with no/mild symptoms at baseline, 40.6%
experienced a ≥4-point increase in AUASI score over the
Table 1 Demographic and clinical characteristics by patient AUA Symptom Index score at baseline









Age, n (%) <0.0001
<45 years 6 (0.1) 5 (0.1) 1 (0.1)
45–50 years 1724 (17.8) 1128 (12.6) 65 (9)
50–55 years 2163 (22.3) 1736 (19.3) 122 (16.8)
55–60 years 2289 (23.6) 2069 (23.1) 165 (22.7)
60–65 years 1965 (20.3) 2054 (22.9) 185 (25.5)
≥65 years 1554 (16) 1982 (22.1) 188 (25.9)
Race, n (%) <0.0001
White 6300 (65.2) 5800 (64.9) 446 (61.7)
Black 736 (7.6) 809 (9) 47 (6.5)
Asian 747 (7.7) 606 (6.8) 59 (8.2)
Hispanic 1563 (16.2) 1452 (16.2) 149 (20.6)
Other 318 (3.3) 273 (3.1) 22 (3)
Unknown 37 (0.4) 34 (0.4) 3 (0.4)
Smoking status, n (%) <0.0001
Never 4613 (47.6) 3936 (43.9) 294 (40.6)
Current 1009 (10.4) 1003 (11.2) 93 (12.8)
Stopped <6 years ago 4075 (42) 4030 (44.9) 338 (46.6)
Unknown 4 (0.04) 5 (0.06) 1 (0.13)
Education level, n (%) <0.0001
High school or lower 1611 (16.8) 1431 (16.1) 157 (21.9)
Vocational or some college 3320 (34.5) 3079 (34.6) 264 (36.9)
College or higher 4685 (48.7) 4394 (49.3) 295 (41.2)
Unknown 85 (0.9) 70 (0.8) 10 (1.3)
Body mass index, kg/m2 0.015
Mean (SD) 27.6 (4.51) 27.9 (4.84) 28.2 (5.68)
Median 27 27.2 27.3
Q1, Q3 24.6,29.9 24.7,30.2 24.7,30.3
Range (10.8–84.1) (10.2–80.0) (7.5–67.2)
BPH medication 2002–2006, n (%) 580 (6) 1217 (13.6) 233 (32.1) <0.0001
BPH diagnosis 2002–2006, n (%) 942 (9.7) 1695 (18.9) 276 (38) <0.0001
BPH procedure 2002–2006, n (%) 26 (0.3) 46 (0.5) 18 (2.5) <0.0001
Urology visit 2002–2006, n (%) 1840 (19) 2205 (24.6) 279 (38.4) <0.0001
AUASI, AUA Symptom Index. *A total of 104 subjects with unknown AUASI scores were excluded.
LUTS progression and treatment in the California Men's Health Study
© 2014 The Authors
BJU International © 2014 BJU International 129
follow-up, while 55.9% experienced a <4-point increase or
decrease and 3.5% reported a 4-point decrease in AUASI
score. The majority of those reporting moderate symptoms at
baseline experienced a ≥4-point decrease in AUASI score
during follow-up (63.5%), whereas 20.1% reported a ≥4-point
increase in AUASI score. Among men who reported severe
symptoms at baseline, approximately one half experienced a
4-point decrease in AUASI score (51.8%), a third (33.0%)
experienced a <4-point change and 15.2% experienced a
≥4-point increase in AUASI score during follow-up (Fig. 1).
Table 2 shows the distribution of BPH clinical characteristics
among the 9640 men who reported no/mild symptoms at
baseline stratified by follow-up AUASI categories. Overall, the
use of services during follow-up to monitor and/or treat BPH
was positively associated with the severity of symptoms at
follow-up. Men who reported severe symptoms at follow-up
were more likely to have a history of BPH diagnosis, BPH
medication use, BPH procedure use and urology visits during
follow-up (Table 2). Among the 3993 men who progressed to
moderate or severe symptoms, only 351 men (8.8%) had a
record of a pharmacological treatment, eight men (2.0%) had
undergone a minimally invasive or surgical procedure and
3634 men (91.0%) had no treatment for BPH during follow-up
(Table 2).
Among men with no/mild symptoms at baseline, BPH
medication use, BPH diagnosis and urology visits were
significantly associated with progression to severe symptoms
over 4 years of follow-up. Those who progressed to severe
symptoms were 4.96 times more likely to have used BPH
medications (adjusted odds ratio [OR] 4.96, 95% CI
3.21–7.65), 1.87 times more likely to have a BPH diagnosis
(adjusted OR 1.87, 95% CI 1.21–2.90) and 1.44 times more
likely to have a urology visit (adjusted OR 1.44, 95% CI
1.01–2.06) during follow-up compared with those who did not
progress to severe symptoms (Table 3).
Discussion
Among this prospectively-followed cohort of racially diverse
men participating in the California Men’s Health Study, 41%
of men reported new onset of moderate/severe LUTS (AUASI
>8) during the 4 years of follow-up. Of those who reported
no/mild symptoms at baseline, >40% experienced clinical
progression as defined by a >4-point increase in AUASI score
during follow-up. Even though a significant number of the
men with no/mild symptoms experienced progression to
moderate/severe LUTS, the vast majority (91%) did not receive
pharmaceutical or surgical treatment therapy during
follow-up.
The present results support the notion that LUTS is a dynamic
condition.While a significant proportion of men experienced
worsening symptoms during follow-up, a subset of men in the
present study saw improvement in their symptoms over the
4-year follow-up. Improvement in symptoms was most
common among men with more severe symptoms and
worsening of symptoms was most prevalent among men
with no/mild symptoms at baseline, which may in part be
influenced by regression to the mean. Our estimates of
progression among men with moderate/severe symptoms are
slightly lower than reported previously in the MrOS study (15
vs 25%). This may be attributable to the inclusion of younger
men in our study sample, whereas MrOS included men aged
≥65 years only. Interestingly, the proportion of men without
significant urinary symptoms at baseline who experienced
clinical progression in their LUTS during follow-up was
greater (41 vs 25%). This is probably because men in the
California Men’s Health Study were followed for a longer
period of 4 years, whereas men in the MrOs study were
followed for 2 years. Our estimates were also greater than
those reported by the OCS, which found 22% of men
without symptoms at baseline experienced progression to
moderate/severe symptoms over 42 months [8]. The difference
in estimates may be partly attributable to a difference in the
proportion of men who received interim treatment which, if
Fig. 1 Follow-up AUA Symptom Index (AUASI) scores and change in AUASI
scores by baseline AUASI scores (N = 19 401).
A  Follow-up AUASI category
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effective, would reduce LUTS over time. Also, the results may
differ because of the inclusion of racial minority groups in our
sample, whereas the OCS included a white-only population.
Differences in both the severity and prevalence of LUTS are
thought to exist across racial/ethnic groups with black and
Hispanic men reporting a greater prevalence of symptoms as
well as more severe symptoms compared with white men
[19,20].
The severity of LUTS and the odds of progression to severe
symptoms were both associated with the use of services to
monitor and/or treat BPH/LUTS in the present study.
Men with severe symptoms at baseline were more likely to
receive a clinical diagnosis of BPH, and have been treated
for BPH/LUTS during follow-up. Of those with no/mild
symptoms at baseline, men who experienced progression to
severe symptoms within 4 years were more likely to have
treatment for BPH/LUTS, urology clinic visits and a BPH
diagnosis during follow-up. Previous studies suggest bother
attributable to LUTS increases with the severity of symptoms
[20,21] and is a strong predictor of whether or not men seek
care for their LUTS [22]; therefore, it is plausible that men
who have more severe symptoms are the ones seeking care for
their LUTS, probably driven by the increased bother they are
experiencing.
Nevertheless, the present data suggest that there remains a
large population of men who experience clinically relevant
progression who are not receiving care for their symptoms.
This is particularly true among men with new-onset LUTS,
as the vast majority of men who did not have significant
LUTS at baseline but reported moderate/severe LUTS at
4-year follow-up had not had a clinic visit nor received
either drug or surgical therapy for their symptoms. The
MrOS study reported a similar phenomenon, as 94% of men
without significant LUTS at baseline remained untreated
during the 2 years of follow-up [9]. These results confirm
findings from previous studies that suggest the majority of
men do not seek care for their LUTS [3,23,24]. Barriers to
seeking care for LUTS include embarrassment about
discussing symptoms, thoughts that it is a normal part of
aging and lack of information regarding treatment options
[25–27]. Efforts should be made to promote the discussion of
LUTS during the clinic visit.
The present results suggest that a sizeable population of
men experience new-onset moderate/severe LUTS within
4 years and therefore may be appropriate candidates for a
self-management programme to manage their symptoms
and/or prolong the initiation of drug or surgical therapy.
Emberton et al. tested a self-management programme and
found it to be as effective in reducing symptom progression
as the standard of care (pharmaceutical management)
[28,29]; however, despite these findings, the consensus that
self-management programmes are effective in reducing LUTS
and the large population of men who may benefit from such
programmes, self-management is not often discussed in clinic
visits and current guidelines do not prioritise self-management
as a treatment strategy, largely because of the lack of an
established curriculum for teaching the self-management
of LUTS.
Table 2 Clinical characteristics of BPH among patients with baseline AUA Symptom Index score in
2002 of 0–7 at 2006 follow-up (N = 9640)*.







BPH medication 2002–2006, n (%) 223 (3.9) 298 (7.8) 53 (32.1) <0.0001
BPH diagnosis 2002–2006, n (%) 403 (7.1) 474 (12.4) 54 (32.7) <0.0001
BPH procedure 2002–2006, n (%) 18 (0.3) 7 (0.2) 1 (0.6) 0.4841
Urology visit 2002–2006, n (%) 956 (16.9) 812 (21.2) 60 (36.4) <0.0001
AUASI, AUA Symptom Index. *A total of 61 subjects with unknown 2006 AUASI score were excluded.
Table 3 Logistic regression predicting AUA Symptom Index (AUASI) scores of ≥20 among patients
with a baseline AUASI score of 0–7.
Variable Unadjusted OR (95% CI) P Adjusted OR* (95% CI) P
Age 1.47 (1.01–2.14) 0.0417 1.04 (0.71–1.54) 0.8258
BPH medications 8.09 (5.77–11.35) <0.0001 4.96 (3.21–7.65) <0.0001
BPH diagnosis 4.74 (3.40–6.61) <0.0001 1.87 (1.21–2.90) 0.0048
BPH procedure 2.33 (0.31–17.23) 0.4086 0.42 (0.05–3.22) 0.4033
Urology visits 2.49 (1.81–3.43) <0.0001 1.44 (1.01–2.06) 0.0449
*Mutually adjusted for the other variables in the table.
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While the present study used a uniquely prospectively
followed, multi-ethnic cohort of men to understand the
incidence and progression of LUTS, there are potential
limitations to consider. The presence of participation bias
cannot be excluded, as 40% of men who completed the
baseline questionnaire did not complete the follow-up
questionnaire. It is possible that those with more significant
symptoms were more likely to complete both and to be
included in the present analysis. This bias may have resulted
in inflated estimates of LUTS progression over 4 years, but
the present results are similar to those reported in previous
large population-based cohorts [7–10]. In addition, data on
bother attributable to LUTS were not available in this cohort
and may have influenced the clinical management of men
who were experiencing symptoms. The study has to date
only included 4 years of follow-up and, therefore, does not
allow conclusions to be drawn about the progression and
management of LUTS over a longer period of time. An
additional round of follow-up is currently being collected,
however, which will allow estimates of 10-year progression
and investigation into associated risk factors in future
analyses.
In conclusion, in the present multi-ethnic cohort of men aged
45–69 years, although 41% of men developed moderate/severe
LUTS over 4 years of follow-up, <10% of these men received
surgical or drug therapy for their symptoms. As expected,
treatment was more common among men who progressed to
severe LUTS, but was still suboptimal. These results suggest
there remains room for improvement in the clinical
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